pure red cell aplasia


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

pure red cell a·pla·si·a

a transitory arrest of red blood cell production that may occur in the course of a hemolytic anemia, often preceded by infection, or as a complication of certain drugs; if the arrest persists, severe anemia may result.
See also: congenital hypoplastic anemia.

pure red cell aplasia

Hematology A type of anemia caused by selective depletion of erythroid cells
Pure red cell aplasia types
Acute Aplastic crisis A condition often preceded by viral gastroenteritis, pneumonitis, primary atypical pneumonia, mumps, viral hepatitis, pregnancy and drug toxicity Clinical Malaise, pallor and other symptoms of a chronic, compensated hemolyzing process Treatment The only effective modality is discontinuance of inculpated drug, if identified
Chronic Either
1.Congenital Diamond-Blackfan disease A condition due to a ↓ in erythrocyte stem cells with ↓ colony-forming units and burst-forming units and a poor response to erythropoietin Treatment Transfusions, corticosteroids or.
2. Acquired 30-50% of chronic acquired PRCA is associated with thymoma, as well as rheumatoid arthritis, lupus erythematosus, chronic active hepatitis, hemolytic anemia and CLL  
.

pure red cell aplasia

A severe failure of production of red blood cells by the bone marrow with normal production of other blood cells. The result is a temporary or persistent severe anaemia. The condition may be caused by some virus infections, some drugs, cancers, rheumatoid arthritis and systemic lupus erythematosus.

aplasia

defective development or complete absence of an organ or tissue due to failure of development.

aplasia cutis
see epitheliogenesis imperfecta.
pure red cell aplasia
selective depression of erythropoiesis with anemia resulting.
segmental aplasia
aplasia of a segment of an organ, e.g. uterus.
References in periodicals archive ?
Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.
There is no cross reaction between peginesatide and anti-erythropoietin antibodies, or between anti-peginesatide antibodies and erythropoietin; thus, pure red cell aplasia is unlikely to occur (Woodburn et al.
Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy.
2005): The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
today announced data from a Phase 2 clinical trial of Hematide[TM] showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA).
INTRODUCTION: Pure red cell aplasia (PRCA) is an uncommon disorder in which maturation arrest occurs in the formation of erythrocytes.
The diseases manifested with PV-B19 are erythema infectiosum, which is common in children, hydrops fetalis, transient pure red cell aplasia in patients with chronic hemolytic anemia, arthralgia - mostly observed in women, and chronic pure red cell aplasia in immunocompromised individuals.
There was no suspicion of antibody-mediated pure red cell aplasia (PRCA).
In January 2003 all persons receiving SC Epoetin alfa were changed to the IV route as cases of pure red cell aplasia were reported in recipients of SC Epoetin alfa in other institutions (MacDougall, 2004).
They include data from a Phase 2 clinical trial evaluating Hematide's ability to raise hemoglobin levels in patients with pure red cell aplasia (PRCA), as well as preclinical studies evaluating the immunogenicity, binding characteristics and mechanism of action of Hematide.